{
    "clinical_study": {
        "@rank": "161388", 
        "acronym": "FAST", 
        "arm_group": [
            {
                "arm_group_label": "Methotrexate", 
                "arm_group_type": "Experimental", 
                "description": "oral methotrexate"
            }, 
            {
                "arm_group_label": "Mycophenolate Mofetil", 
                "arm_group_type": "Experimental", 
                "description": "oral mycophenolate mofetil"
            }
        ], 
        "brief_summary": {
            "textblock": "In the First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial, the\n      investigators propose to establish which immunosuppressive therapy, methotrexate or\n      mycophenolate mofetil, is more effective as a first-line, corticosteroid-sparing agent for\n      the treatment of non-infectious uveitis in a block-randomized, observer-masked, comparative\n      effectiveness trial."
        }, 
        "brief_title": "Methotrexate and Mycophenolate Mofetil for UVEITIS", 
        "completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Uveitis", 
        "condition_browse": {
            "mesh_term": [
                "Uveitis", 
                "Chorioretinitis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  All the following criteria must be met at enrollment:\n\n        Historical non-infectious intermediate, anterior and intermediate, posterior or panuveitis\n        in at least one eye\n\n        Active inflammation within the last 90 days, defined by the presence of any of the\n        following (in at least one eye) according to SUN criteria:\n\n          -  2+ anterior chamber cells\n\n          -  2+ vitreous haze active retinal or choroidal lesions\n\n        At least one of the following criteria must be met before or at enrollment:\n\n          1. Active inflammation after 4 weeks of high-dose (1mg/kg prednisone equivalent)\n             corticosteroid treatment or 4 weeks following a regional corticosteroid injection\n\n          2. Treatment with oral corticosteroids resulting in a reduction of inflammation,\n             followed by an increase in inflammation (of at least 1 grade in anterior chamber\n             cells or vitreous haze or a change of non-active to active lesions) when\n             corticosteroid is tapered, in the 2 weeks prior to enrollment\n\n          3. Known chronic condition necessitating corticosteroid-sparing immunosuppressive\n             treatment\n\n        At least 1+ anterior chamber cells and/or 1+ vitreous haze and/or active retinal/choroidal\n        lesions (bullous serous retinal detachment qualifies) in at least one eye at enrollment.\n\n        Willingness to start corticosteroid treatment at 1mg/kg or 60mg a day of prednisone,\n        whichever is less\n\n        Willingness to abstain from alcohol (2 drinks per month is okay)\n\n        Willingness to use an acceptable method of contraception during the study period (i.e.\n        pharmacologics, devices, barrier methods) or abstinence.\n\n        Exclusion Criteria:\n\n        Any infectious cause of uveitis\n\n        Media opacity (such as cataract and/or corneal scar) and/or extensive posterior synechiae\n        such that examination of the posterior segment is not possible in both eyes\n\n        Chronic hypotony (IOP < 5 mm Hg for > 3 months) in both eyes\n\n        Prior use of any immunosuppressive drug other than prednisone\n\n        Periocular or intravitreal corticosteroid injection in the past 4 weeks\n\n        Fluocinolone acetonide implant in either eye in < 3 years\n\n        Intraocular surgery in < 30 days, or planning on getting surgery within the next 6 months\n\n        Best spectacle-corrected visual acuity (BSCVA) of hand motions or worse in better eye\n\n        < 16 years of age at enrollment\n\n        Planning to conceive during the study period, pregnant or breast-feeding (blood or urine\n        pregnancy test for all females, excluding those who are post-menopausal is mandatory)*\n\n        Cancer (If a patient has a history of non-melanoma skin cancer they can still be\n        considered for inclusion in this study, provided it is not  currently active.\n\n        Systemic autoimmune disease anticipated to dictate treatment course\n\n        Abnormal CBC (\u2264 2,500 white blood cells and/or \u2264 75,000 platelets and/or \u22649 hemoglobin)\n        within 4 weeks prior to enrollment*\n\n        Abnormal alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) \u2265 2 times\n        the upper limit of normal for the lab and/or creatinine \u2265 1.5 within 4 weeks prior to\n        enrollment*\n\n        Evidence of active tuberculosis, HIV infection, syphilis, or hepatitis B or C (patients\n        must have a tuberculin skin test, or interferon-gamma release assay, a chest radiograph,\n        RPR/VDRL, FTA-ABS, or other treponemal tests, Hepatitis B surface antigen, Hepatitis C\n        antibody tests, and HIV test within 90 days prior to enrollment)**\n\n        *Testing required within 14 days prior to enrollment; **Testing required within 90 days\n        prior to enrollment."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "16 Years"
        }, 
        "enrollment": {
            "#text": "216", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01829295", 
            "org_study_id": "EY021125-01"
        }, 
        "intervention": {
            "arm_group_label": [
                "Methotrexate", 
                "Mycophenolate Mofetil"
            ], 
            "intervention_name": "Immunosuppressive therapy (oral methotrexate,  oral mycophenolate mofetil)", 
            "intervention_type": "Drug", 
            "other_name": "antimetabolite treatment"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Antimetabolites", 
                "Methotrexate", 
                "Immunosuppressive Agents", 
                "Mycophenolate mofetil", 
                "Mycophenolic Acid"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 8, 2014", 
        "location": [
            {
                "contact": {
                    "email": "rachel.weinrib@ucsf.edu", 
                    "last_name": "Rachel Weinrib, MPH", 
                    "phone": "415-476-6687"
                }, 
                "contact_backup": {
                    "email": "sally.tsang@ucsf.edu", 
                    "last_name": "Sally Tsang, MA", 
                    "phone": "4154761442"
                }, 
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94143"
                    }, 
                    "name": "Proctor Foundation"
                }, 
                "investigator": {
                    "last_name": "Nisha Acharya, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "debrgold@yahoo.com", 
                    "last_name": "Debra Goldstein, MD"
                }, 
                "contact_backup": {
                    "email": "annaliza.castro@gmail.com", 
                    "last_name": "Anna Castro-Malek"
                }, 
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60611"
                    }, 
                    "name": "Northwestern University"
                }, 
                "investigator": {
                    "last_name": "Debra Goldstein, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "eric.suhler@va.gov", 
                    "last_name": "Eric Suhler, MD"
                }, 
                "contact_backup": {
                    "email": "gilest@ohsu.edu", 
                    "last_name": "Tracy Giles", 
                    "phone": "503-494-0482"
                }, 
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97239"
                    }, 
                    "name": "Oregon Health and Science University - Casey Eye Institute"
                }, 
                "investigator": {
                    "last_name": "Eric Suhler, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "limllp@unimelb.edu.au", 
                    "last_name": "Lyndell Lim, MD"
                }, 
                "contact_backup": {
                    "email": "jl.morrison@unimelb.edu.au", 
                    "last_name": "Julie Morrison"
                }, 
                "facility": {
                    "address": {
                        "city": "Melbourne", 
                        "country": "Australia", 
                        "state": "Victoria", 
                        "zip": "3002"
                    }, 
                    "name": "Royal Victorian Eye and Ear Hospital"
                }, 
                "investigator": {
                    "last_name": "Lyndell Lim, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "kanakath@gmail.com", 
                    "last_name": "Anuradha, MD"
                }, 
                "contact_backup": {
                    "email": "princycrc@gmail.com", 
                    "last_name": "Sarah Princy"
                }, 
                "facility": {
                    "address": {
                        "city": "Coimbatore", 
                        "country": "India", 
                        "state": "Tamil Nadu"
                    }, 
                    "name": "Aravind Eye Hospital"
                }, 
                "investigator": {
                    "last_name": "Anu Kanakath, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "rathinam@aravind.org", 
                    "last_name": "S.R. Rathinam, MD PhD"
                }, 
                "contact_backup": {
                    "email": "k.gobibpharm@gmail.com", 
                    "last_name": "Gobinath Kanagaraj"
                }, 
                "facility": {
                    "address": {
                        "city": "Madurai", 
                        "country": "India", 
                        "state": "Tamil Nadu"
                    }, 
                    "name": "Aravind Eye Hospital"
                }, 
                "investigator": {
                    "last_name": "S.R. Rathinam, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "lourdes.arellanes@apec.com.mx", 
                    "last_name": "Lourdes Arellanes, MD"
                }, 
                "contact_backup": {
                    "email": "yokoburgoa@yahoo.com", 
                    "last_name": "Yoko Burgoa"
                }, 
                "facility": {
                    "address": {
                        "city": "Mexico City", 
                        "country": "Mexico", 
                        "state": "Mexico, D.F.", 
                        "zip": "04030"
                    }, 
                    "name": "Asociacion Para Evita La Ceguera en Mexico"
                }, 
                "investigator": {
                    "last_name": "Lourdes Arellanes, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Australia", 
                "India", 
                "Mexico"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial", 
        "overall_contact": {
            "email": "nisha.acharya@ucsf.edu", 
            "last_name": "Nisha Acharya, MD", 
            "phone": "4154768183"
        }, 
        "overall_contact_backup": {
            "email": "rachel.weinrib@ucsf.edu", 
            "last_name": "Rachel Weinrib, MPH", 
            "phone": "4154676687"
        }, 
        "overall_official": {
            "affiliation": "University of California, San Francisco", 
            "last_name": "Nisha Acharya, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Data and Safety Monitoring Board", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Controlled ocular inflammation (\u2264 0.5+ anterior chamber cells, \u2264 0.5+ vitreous haze, no active retinal/choroidal lesions in both eyes) with \u2264 7.5 mg/day of oral prednisone and \u2264 2 drops/day of topical 1% prednisolone acetate.", 
            "measure": "Treatment Success", 
            "safety_issue": "No", 
            "time_frame": "6 Months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01829295"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "University of California, San Francisco", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Aravind Eye Hospitals, India", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Oregon Health and Science University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Asociacion Para Evitar La Ceguera en Mexico", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Royal Victoria Eye and Ear Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Northwestern University", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "University of California, San Francisco", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}